May 21st 2024
Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Treatment Armamentarium for HER2+ Metastatic Breast Cancer
Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.
Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease
Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.
Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+/HER2– Breast Cancer
December 8th 2022Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
Yoga May Improve DFS, OS in Patients with Non-Metastatic Breast Cancer
December 7th 2022Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.
Despite Similar Recurrence Scores, Black Patients With HR+ Breast Cancer Have Worse Outcomes
December 7th 2022Non-Hispanic Black patients with HR+ breast cancer experienced worse overall outcomes compared with other patient subgroups despite similar recurrence scores, according to a recent analysis of the phase 3 RxPONDER trial.
Abemaciclib Plus Endocrine Therapy Improved Survival in HR+/HER2– High-Risk Early Breast Cancer
December 7th 2022The prespecified overall survival analysis of the phase 3 monarchE trial when abemaciclib was added to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Integrative Oncology in Young Women With Breast Cancer
Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Camizestrant Meets PFS End Point Vs Fulvestrant in ER+ Advanced/Metastatic Breast Cancer
October 30th 2022Oral selective estrogen receptor degrader camizestrant elicited a statistically significant and clinically meaningful progression-free survival benefit compared with fulvestrant among patients with estrogen receptor–positive locally advanced or metastatic breast cancer.